This review makes a critical evaluation of 61 peer‐reviewed manuscripts that use a docking
step in a virtual screening (VS) protocol to predict SARS‐CoV‐2 M‐pro (M‐pro) inhibitors in …

The global coronavirus disease-19 (COVID-19) has affected more than 140 million and
killed more than 3 million people worldwide as of April 20, 2021. The novel human severe …

The novel coronavirus, SARS-CoV-2, has been identified as the causative agent for the
current coronavirus disease (COVID-19) pandemic. 3CL protease (3CLpro) plays a pivotal …

The main protease (Mpro, 3CLpro) of SARS-CoV-2 is an attractive target in coronaviruses
because of its crucial involvement in viral replication and transcription. Here, we report on …

The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
has called for an urgent need for dedicated antiviral therapeutics. Metal complexes are …

Corona virus is quickly spreading around the world. The goal of viral management is to
disrupt the virus's life cycle, minimize lung damage, and alleviate severe symptoms …

In this review, we collected 1765 severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) M-pro inhibitors from the bibliography and other sources, such as the COVID …

Taking advantage of the uniquely constricted active site of SARS-CoV-2 Nsp14
methyltransferase, we have designed bisubstrate inhibitors interacting with the SAM and …

The ongoing COVID-19 pandemic caused by SARS-CoV-2 has raised global concern for
public health and economy. The development of therapeutics and vaccines to combat this …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has forced the
development of direct-acting antiviral drugs due to the coronavirus disease 2019 (COVID …